STOCK TITAN
  1. Home
  2. News
  3. ENDV

Endonovo Therapeutics Inc - ENDV STOCK NEWS

IMPACT
SENTIMENT
ENDV : OTC
Endonovo's SofPulse® Secures Taiwan FDA Approval
fda approval
IMPACT
SENTIMENT
ENDV : OTC
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
IMPACT
SENTIMENT
ENDV : OTC
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
IMPACT
SENTIMENT
ENDV : OTC
Endonovo Pending Agreement to Develop Telehealth Division
IMPACT
SENTIMENT
ENDV : OTC
Endonovo Launches SofPulse® into the Veterans Administration
IMPACT
SENTIMENT
ENDV : OTC
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
clinical trial
IMPACT
SENTIMENT
ENDV : OTC
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
partnership
IMPACT
SENTIMENT
ENDV : OTC
Endonovo Announces Partnership with Santana Lead Singer Andy Vargas
partnership
IMPACT
SENTIMENT
ENDV : OTC
Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
IMPACT
SENTIMENT
ENDV : OTC
Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan
Stock ENDV logo
Endonovo Therapeutics Inc
OTC:ENDV

ENDV Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About ENDV

endonovo therapeutics (otcqb: endv) is an innovative biotechnology company developing a bioelectronic approach to regenerative medicine. endonovo's immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. endonovo's cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and time-varying electromagnetic fields (tvemf) for tissue engineering and cell therapies.